Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 41

1.

Dual Strands of Pre-miR-149 Inhibit Cancer Cell Migration and Invasion through Targeting FOXM1 in Renal Cell Carcinoma.

Okato A, Arai T, Yamada Y, Sugawara S, Koshizuka K, Fujimura L, Kurozumi A, Kato M, Kojima S, Naya Y, Ichikawa T, Seki N.

Int J Mol Sci. 2017 Sep 13;18(9). pii: E1969. doi: 10.3390/ijms18091969.

2.

Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus.

Kurozumi A, Okada Y, Arao T, Kobayashi T, Masuda D, Yamashita S, Tanaka Y.

J Diabetes Investig. 2017 Aug 29. doi: 10.1111/jdi.12739. [Epub ahead of print]

3.

Regulation of spindle and kinetochore-associated protein 1 by antitumor miR-10a-5p in renal cell carcinoma.

Arai T, Okato A, Kojima S, Idichi T, Koshizuka K, Kurozumi A, Kato M, Yamazaki K, Ishida Y, Naya Y, Ichikawa T, Seki N.

Cancer Sci. 2017 Jul 26. doi: 10.1111/cas.13331. [Epub ahead of print]

4.

Impact of novel miR-145-3p regulatory networks on survival in patients with castration-resistant prostate cancer.

Goto Y, Kurozumi A, Arai T, Nohata N, Kojima S, Okato A, Kato M, Yamazaki K, Ishida Y, Naya Y, Ichikawa T, Seki N.

Br J Cancer. 2017 Jul 25;117(3):409-420. doi: 10.1038/bjc.2017.191. Epub 2017 Jun 22.

PMID:
28641312
5.

Regulation of ITGA3 by the anti-tumor miR-199 family inhibits cancer cell migration and invasion in head and neck cancer.

Koshizuka K, Hanazawa T, Kikkawa N, Arai T, Okato A, Kurozumi A, Kato M, Katada K, Okamoto Y, Seki N.

Cancer Sci. 2017 Aug;108(8):1681-1692. doi: 10.1111/cas.13298. Epub 2017 Jul 4.

6.

Dual strands of pre-miR‑150 (miR‑150‑5p and miR‑150‑3p) act as antitumor miRNAs targeting SPOCK1 in naïve and castration-resistant prostate cancer.

Okato A, Arai T, Kojima S, Koshizuka K, Osako Y, Idichi T, Kurozumi A, Goto Y, Kato M, Naya Y, Ichikawa T, Seki N.

Int J Oncol. 2017 Jul;51(1):245-256. doi: 10.3892/ijo.2017.4008. Epub 2017 May 17.

PMID:
28534948
7.

Clinical Features of Patients with Basedow's Disease and High Serum IgG4 Levels.

Torimoto K, Okada Y, Kurozumi A, Narisawa M, Arao T, Tanaka Y.

Intern Med. 2017;56(9):1009-1013. doi: 10.2169/internalmedicine.56.7824. Epub 2017 May 1.

8.

Twenty-four-hour variations in blood glucose level in Japanese type 2 diabetes patients based on continuous glucose monitoring.

Hajime M, Okada Y, Mori H, Otsuka T, Kawaguchi M, Miyazaki M, Kuno F, Sugai K, Sonoda S, Tanaka K, Kurozumi A, Narisawa M, Torimoto K, Arao T, Tanaka Y.

J Diabetes Investig. 2017 Apr 18. doi: 10.1111/jdi.12680. [Epub ahead of print]

9.
10.
11.

Comparative analysis of the effects of alogliptin and vildagliptin on glucose metabolism in type 2 diabetes mellitus.

Tanaka K, Okada Y, Mori H, Miyazaki M, Kuno F, Sonoda S, Sugai K, Hajime M, Kurozumi A, Narisawa M, Torimoto K, Arao T, Mine S, Tanaka Y.

Endocr J. 2017 Feb 27;64(2):179-189. doi: 10.1507/endocrj.EJ16-0341. Epub 2016 Nov 12.

12.

Excess Visceral Adipose Tissue Worsens the Vascular Endothelial Function in Patients with Type 2 Diabetes Mellitus.

Kurozumi A, Okada Y, Arao T, Tanaka Y.

Intern Med. 2016;55(21):3091-3095. Epub 2016 Nov 1.

13.

Regulation of MMP13 by antitumor microRNA-375 markedly inhibits cancer cell migration and invasion in esophageal squamous cell carcinoma.

Osako Y, Seki N, Kita Y, Yonemori K, Koshizuka K, Kurozumi A, Omoto I, Sasaki K, Uchikado Y, Kurahara H, Maemura K, Natsugoe S.

Int J Oncol. 2016 Dec;49(6):2255-2264. doi: 10.3892/ijo.2016.3745. Epub 2016 Oct 21.

14.

The tumor-suppressive microRNA-23b/27b cluster regulates the MET oncogene in oral squamous cell carcinoma.

Fukumoto I, Koshizuka K, Hanazawa T, Kikkawa N, Matsushita R, Kurozumi A, Kato M, Okato A, Okamoto Y, Seki N.

Int J Oncol. 2016 Sep;49(3):1119-29. doi: 10.3892/ijo.2016.3602. Epub 2016 Jul 4.

PMID:
27573718
15.

The microRNA signature of patients with sunitinib failure: regulation of UHRF1 pathways by microRNA-101 in renal cell carcinoma.

Goto Y, Kurozumi A, Nohata N, Kojima S, Matsushita R, Yoshino H, Yamazaki K, Ishida Y, Ichikawa T, Naya Y, Seki N.

Oncotarget. 2016 Sep 13;7(37):59070-59086. doi: 10.18632/oncotarget.10887.

16.

Factors influencing inter-day glycemic variability in diabetic outpatients receiving insulin therapy.

Mori H, Okada Y, Kurozumi A, Narisawa M, Tanaka Y.

J Diabetes Investig. 2017 Jan;8(1):69-74. doi: 10.1111/jdi.12551. Epub 2016 Aug 18.

17.

Aberrantly expressed microRNAs in bladder cancer and renal cell carcinoma.

Kurozumi A, Goto Y, Okato A, Ichikawa T, Seki N.

J Hum Genet. 2017 Jan;62(1):49-56. doi: 10.1038/jhg.2016.84. Epub 2016 Jun 30. Review.

PMID:
27357429
18.

Regulation of metastasis-promoting LOXL2 gene expression by antitumor microRNAs in prostate cancer.

Kato M, Kurozumi A, Goto Y, Matsushita R, Okato A, Nishikawa R, Fukumoto I, Koshizuka K, Ichikawa T, Seki N.

J Hum Genet. 2017 Jan;62(1):123-132. doi: 10.1038/jhg.2016.68. Epub 2016 Jun 9.

PMID:
27278788
19.

Pancreas-protective effect of rituximab for acute-onset type 1 diabetes in the honeymoon period: a case report.

Kurozumi A, Okada Y, Arao T, Miyazaki Y, Yoshikawa M, Torimoto K, Kubo S, Nakayamada S, Tanaka Y.

Endocrinol Diabetes Metab Case Rep. 2016;2016:160020. doi: 10.1530/EDM-16-0020. Epub 2016 May 1.

20.

Direct regulation of LAMP1 by tumor-suppressive microRNA-320a in prostate cancer.

Okato A, Goto Y, Kurozumi A, Kato M, Kojima S, Matsushita R, Yonemori M, Miyamoto K, Ichikawa T, Seki N.

Int J Oncol. 2016 Jul;49(1):111-22. doi: 10.3892/ijo.2016.3522. Epub 2016 May 16.

Supplemental Content

Loading ...
Support Center